

3 February 2021

*This press release is an English translation of the Swedish original. In the event of any discrepancies, the Swedish version shall prevail*

## **Information about the trading in subscription rights and BTA**

**Stayble Therapeutics AB ("Stayble" or the "Company") hereby informs that the first day of trading in subscription rights and paid subscribed share ("BTA"), in connection with the Company's ongoing rights issue, has been rescheduled for tomorrow, Thursday, 4 February 2021 due to an administrative and technical delay. The first day of trading in subscription rights and BTA was previously planned for today, 3 February 2021.**

Due to an administrative and technical delay, Stayble hereby informs that the subscription rights will be traded on Nasdaq First North Growth Market during the period 4 - 15 February 2021. Trading in BTA will take place on Nasdaq First North Growth Market as of 4 February 2021 and will continue until the Swedish Companies Registration Office has registered the rights issue. This registration is expected to take place in mid-March 2021.

### **For more information about the rights issue**

Sedermersa Fondkommission

Phone: +46 40 615 14 10

E-mail: [info@sedermersa.se](mailto:info@sedermersa.se)

[www.sedermersa.se](http://www.sedermersa.se)

### **For more information about Stayble**

Andreas Gerward, CEO Stayble Therapeutics AB

Phone: +46 730 808 397

E-mail: [andreas.gerward@stayble.se](mailto:andreas.gerward@stayble.se)

### **About Stayble Therapeutics AB**

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once, and the effect is expected to remain throughout the entirety of the patient's life and to require minimal rehabilitation. The Company is now focusing on the continued clinical development and is currently conducting a clinical phase 2b study. Stayble's vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company's Certified Adviser and can be reached at +46 (0) 8 503 015 50 or e-mail [ca@mangold.se](mailto:ca@mangold.se)